Literature DB >> 11058829

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data.

.   

Abstract

In order to distinguish patients with cirrhosis from those with chronic hepatitis, multivariate discriminant analysis was performed using common laboratory data. A total of 205 consecutive patients were diagnosed by peritoneoscopy and biopsy as having chronic liver disease caused by hepatitis C virus (HCV), 168 with chronic hepatitis and 37 with cirrhosis. Twenty variables and their natural logarithmic transformation were employed in the multivariate analysis. After stepwise variable selection, the following function was finally obtained to discriminate the disease severity, z=0.120xgamma-globulin (%)+0.423xln (hyaluronate) (µg l(-1))-0.059xplatelet (x10(4) counts per mm(3))-0.364xsex (male, 1; female, 2)-3.953. Since the function contained an expression of logarithm and was slightly troublesome to apply, we prepared another discriminant function composed of usual figures without logarithmic transformation, z=0.124x(gamma-globulin (%))+0.001x(hyaluronate) (µg l(-1))-0.075x(platelet (x10(4) counts per mm(3)))-0.413xgender (male, 1; female, 2)-2.005. When a positive result is calculated in the latter equation, the diagnosis of the liver disease indicates cirrhosis, and negative result chronic hepatitis. Accuracy of the two discriminant functions was 90.3 and 91.2%, respectively. A concise linear discriminant function could successfully differentiate liver cirrhosis from chronic hepatitis with an accuracy of 91.2%.

Entities:  

Year:  2000        PMID: 11058829     DOI: 10.1016/s1386-6346(00)00074-7

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  17 in total

Review 1.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

2.  Support vector machine-based feature selection for classification of liver fibrosis grade in chronic hepatitis C.

Authors:  Zheng Jiang; Kazunobu Yamauchi; Kentaro Yoshioka; Kazuma Aoki; Susumu Kuroyanagi; Akira Iwata; Jun Yang; Kai Wang
Journal:  J Med Syst       Date:  2006-10       Impact factor: 4.460

3.  Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection.

Authors:  Yusuke Kawamura; Norio Akuta; Hitomi Sezaki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2005-09       Impact factor: 7.527

4.  Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

Authors:  Norio Akuta; Joji Toyota; Yoshiyasu Karino; Fusao Ikeda; Akio Ido; Katsuaki Tanaka; Koichi Takaguchi; Atsushi Naganuma; Eiichi Tomita; Kazuaki Chayama; Shigetoshi Fujiyama; Yukiko Inada; Hitoshi Yoshiji; Hideaki Watanabe; Hiroki Ishikawa; Fiona McPhee; Stephanie Noviello; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2018-03-02       Impact factor: 7.527

5.  Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma.

Authors:  Hiroshi Abe; Yuta Aida; Haruya Ishiguro; Kai Yoshizawa; Tamihiro Miyazaki; Munenori Itagaki; Satoshi Sutoh; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

6.  Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections.

Authors:  Naoki Tanaka; Akira Horiuchi; Takahiro Yamaura; Michiharu Komatsu; Takahide Yokoyama; Shinji Okaniwa; Tadanobu Nagaya; Kaname Yoshizawa; Kendo Kiyosawa; Toshifumi Aoyama; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2009-04-08       Impact factor: 7.527

7.  Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

Authors:  Joji Toyota; Yoshiyasu Karino; Fumitaka Suzuki; Fusao Ikeda; Akio Ido; Katsuaki Tanaka; Koichi Takaguchi; Atsushi Naganuma; Eiichi Tomita; Kazuaki Chayama; Shigetoshi Fujiyama; Yukiko Inada; Hitoshi Yoshiji; Hideaki Watanabe; Hiroki Ishikawa; Wenhua Hu; Fiona McPhee; Misti Linaberry; Philip D Yin; Eugene Scott Swenson; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2016-08-09       Impact factor: 7.527

8.  Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus.

Authors:  Ikue Noda; Mikiya Kitamoto; Hideki Nakahara; Ryohei Hayashi; Tomoaki Okimoto; Yoshio Monzen; Hiroyasu Yamada; Masaru Imagawa; Nobuhiko Hiraga; Junko Tanaka; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2009-10-29       Impact factor: 7.527

9.  Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients.

Authors:  Hiromi Saneto; Masahiro Kobayashi; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2008-12-24       Impact factor: 7.527

10.  Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo.

Authors:  Hiroshi Abe; Kai Yoshizawa; Takuya Kitahara; Ryoichi Aizawa; Mika Matsuoka; Yoshio Aizawa
Journal:  J Gastroenterol       Date:  2008-12-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.